{"created":"2023-05-15T09:08:46.361666+00:00","id":16446,"links":{},"metadata":{"_buckets":{"deposit":"14a4c2ed-a51b-4629-879a-7282a00f7dfc"},"_deposit":{"created_by":14,"id":"16446","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"16446"},"status":"published"},"_oai":{"id":"oai:sapmed.repo.nii.ac.jp:00016446","sets":["1875:1879:2192"]},"author_link":["32471","32472","32473","32474","32475","32476"],"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-09-30","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"40","bibliographicPageStart":"35","bibliographicVolumeNumber":"43","bibliographic_titles":[{"bibliographic_title":"函館医学誌 = Hakodate medical journal"},{"bibliographic_title":"Hakodate medical journal","bibliographic_titleLang":"en"}]}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"2015年12月，24週に１回皮下投与するリュープロレリン酢酸塩22.5mg 注射剤（６ヵ月製剤）が前立腺癌または閉経前乳癌の効能・効果にて発売となり，利便性や患者の負担軽減について期待されている｡当院においては発売後の翌月に採用となったが，2016年９月現在では前立腺癌の患者に１例も使用されていなかった｡そのため，同年10月，12週に１回皮下投与するリュープロレリン酢酸塩11.25mg 注射剤（３ヵ月製剤）を使用している患者78名に対して，6 ヵ月製剤の認知度のアンケート調査を実施した（回収率84.6％）｡その結果，ほとんどの患者は６ヵ月製剤が発売になったことを知らず（92.4％），６ヵ月製剤に変更したいかの問いには，医師にお任せするが78.8％を占めた｡また，アンケート後に６ヵ月製剤に変更になった患者40名に対し，６ヵ月製剤の満足度アンケート調査を実施したところ（回収率75.0％），医療費が安くなったという実感がある患者は33.3％であった｡身体的な面では，注射時の痛みが減ったと回答した患者は70.0％，注射部位の発赤や硬結の症状はかわらないと回答したものは80.0％であった｡以上の結果より，患者は新規薬剤に関する情報が不足しているケースもあることから，治療に対する患者の満足を高めていくためにも，医療者が積極的に最新の情報提供をおこなっていく必要性が示唆された｡","subitem_description_type":"Abstract"}]},"item_5_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"市立函館病院"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0910-0725","subitem_source_identifier_type":"ISSN"}]},"item_5_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"坂田, 幸雄"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"阿部, ゆかり"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"及川, 真亮"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"小島, 由太"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"西村, 祥二"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"小林, 道也"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-25"}],"displaytype":"detail","filename":"n0910072543135.pdf","filesize":[{"value":"2.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"n0910072543135.pdf","url":"https://sapmed.repo.nii.ac.jp/record/16446/files/n0910072543135.pdf"},"version_id":"f0fc54e5-575c-4b9c-99fb-bf87d4a7d269"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Leuprorelin acetate","subitem_subject_scheme":"Other"},{"subitem_subject":"Patients questionnaire","subitem_subject_scheme":"Other"},{"subitem_subject":"Patients awareness","subitem_subject_scheme":"Other"},{"subitem_subject":"Medical bills","subitem_subject_scheme":"Other"},{"subitem_subject":"Patients satisfaction","subitem_subject_scheme":"Other"},{"subitem_subject":"Leuprorelin acetate","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Patients questionnaire","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Patients awareness","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Medical bills","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Patients satisfaction","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"technical report","resourceuri":"http://purl.org/coar/resource_type/c_18gh"}]},"item_title":"リュープロレリン酢酸塩11.25mg 製剤から22.5mg 製剤への切り替えにおける前立腺癌治療患者の認知度と意識調査","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"リュープロレリン酢酸塩11.25mg 製剤から22.5mg 製剤への切り替えにおける前立腺癌治療患者の認知度と意識調査","subitem_title_language":"ja"}]},"item_type_id":"5","owner":"14","path":["2192"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-02-25"},"publish_date":"2020-02-25","publish_status":"0","recid":"16446","relation_version_is_last":true,"title":["リュープロレリン酢酸塩11.25mg 製剤から22.5mg 製剤への切り替えにおける前立腺癌治療患者の認知度と意識調査"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-12-13T03:02:36.312568+00:00"}